文献速递脊柱关节炎

古塞奇尤单抗对银屑病关节炎附着点炎和指趾炎的II期研究

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.
PubMed 文献 · RMD Open · 2020-01-01

这项II期随机安慰剂对照双盲试验纳入149例活动性银屑病关节炎患者,评估古塞奇尤单抗100mg对附着点炎和指趾炎的影响。第24周时古塞奇尤单抗组附着点炎和指趾炎平均改善及消退比例均优于安慰剂组,疗效持续至第56周,且ACR20应答与改善相关。

要点

  • 古塞奇尤单抗组第24周附着点炎和指趾炎平均改善及消退比例优于安慰剂。
  • 疗效持续至第56周,安慰剂交叉组改善与古塞奇尤单抗组相似。
  • ACR20应答者附着点炎和指趾炎改善优于无应答者。

核心结论

  • 第24周古塞奇尤单抗组附着点炎和指趾炎平均改善及消退比例均优于安慰剂组。
  • ACR20应答与附着点炎和指趾炎改善相关。

研究设计与样本

  • II期随机安慰剂对照双盲试验,纳入149例活动性银屑病关节炎成人患者。
  • 患者随机接受古塞奇尤单抗100mg或安慰剂皮下注射,第0、4周及之后每8周给药,安慰剂组第24周交叉至古塞奇尤单抗。

主要发现

  • 基线时107例有附着点炎(平均评分2.7),81例有指趾炎(平均指趾炎评分5.7)。
  • 第24周古塞奇尤单抗组附着点炎和指趾炎平均改善大于安慰剂组,并持续至第56周。
  • 第56周时安慰剂交叉组的附着点炎和指趾炎平均改善与古塞奇尤单抗组相似。
  • 第24周古塞奇尤单抗组ACR20应答者附着点炎和指趾炎改善大于无应答者。

关键数值与推荐

  • 附着点炎采用利兹附着点炎指数(0-6)评估。
  • 指趾炎按每个指趾0-3分评分。
  • 入组要求≥3个肿胀关节和≥3个压痛关节且C反应蛋白≥0.3 mg/dL。

临床怎么用

  • 古塞奇尤单抗可改善活动性银屑病关节炎患者的附着点炎和指趾炎。
  • 治疗中可关注ACR20应答,其与附着点炎和指趾炎改善相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of patients with active psoriatic arthritis (PsA). METHODS: This was a phase II, randomised, placebo-controlled, double-blind trial of adults with active PsA (≥3 swollen and ≥3 tender joints and C reactive protein ≥0.3 mg/dL) despite conventional synthetic disease-modifying anti-rheumatic drug, non-steroidal anti-inflammatory drug, and/or oral corticosteroid therapy. Patients were randomised to subcutaneous injections of guselkumab 100 mg or placebo at weeks 0, 4 and every 8 weeks, with placebo crossover to guselkumab at week 24. Dactylitis was scored on a scale of 0-3 on each digit; enthesitis was assessed using the Leeds Enthesitis Index (0-6). Other assessments included American College of Rheumatology (ACR) and Psoriasis Area and Severity Index responses. RESULTS: Of 149 randomised patients, 107 patients had enthesitis (mean score=2.7) and 81 patients had dactylitis (mean dactylitis score=5.7) at baseline. Mean improvements in enthesitis and dactylitis at week 24 were greater in the guselkumab group versus placebo and sustained through week 56. Similar results were observed for the proportions of patients with resolution of enthesitis and dactylitis. At week 56, mean improvements in enthesitis and dactylitis among patients who switched from placebo to guselkumab treatment were similar to those in the guselkumab group. In the guselkumab group, ACR20 responders had greater improvements in enthesitis and dactylitis versus non-responders (week 24). CONCLUSIONS: At week 24, the guselkumab group had greater mean improvements in enthesitis and dactylitis and greater proportions of patients with resolution of enthesitis and dactylitis versus placebo. ACR20 response was associated with improvements in enthesitis and dactylitis. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT02319759.URL: https://clinicaltrials.gov/ct2/show/NCT02319759; Registered 18 December 2014.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Mease PJ, Gladman DD, Deodhar A, et al. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. RMD Open. 2020. PMID: 32665433. doi:10.1136/rmdopen-2020-001217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。